» Articles » PMID: 15671045

Myocardial Infarction Increases ACE2 Expression in Rat and Humans

Overview
Journal Eur Heart J
Date 2005 Jan 27
PMID 15671045
Citations 219
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Angiotensin converting enzyme (ACE) 2 catalyses the cleavage of angiotensin (Ang) I to Ang 1-9 and of Ang II to Ang 1-7. ACE2 deficiency impairs cardiac contractility and upregulates hypoxia-induced genes, suggesting a link with myocardial ischaemia. We studied the expression of ACE2 after myocardial infarction (MI) in the rat as well as in human failing hearts.

Methods And Results: Rats were killed at days 1, 3, and 28 after MI, or treated for 4 weeks with the ACE inhibitor ramipril (1 mg/kg). Cardiac gene and protein expression of ACE and ACE2 were assessed by quantitative real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry/activity assays/in vitro autoradiography, respectively. Both ACE (P = 0.022) and ACE2 (P = 0.015) mRNA increased in the border/infarct area compared with the viable area at day 3 after MI. By day 28, increases in ACE (P = 0.005) and ACE2 (P = 0.006) mRNA were also seen in the viable myocardium of MI rats compared with myocardium of control rats. ACE2 protein localized to macrophages, vascular endothelium, smooth muscle, and myocytes. Ramipril attenuated cardiac hypertrophy and inhibited cardiac ACE. In contrast, ramipril had no effect on cardiac ACE2 mRNA, which remained elevated in all areas of the MI rat heart. Immunoreactivity of both ACE and ACE2 increased in failing human hearts.

Conclusion: The increase in ACE2 after MI suggests that it plays an important role in the negative modulation of the renin angiotensin system in the generation and degradation of angiotensin peptides after cardiac injury.

Citing Articles

Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions.

Kamdar A, Sykes R, Thomson C, Mangion K, Ang D, Lee M Infect Med (Beijing). 2024; 3(4):100147.

PMID: 39649442 PMC: 11621938. DOI: 10.1016/j.imj.2024.100147.


SARS-CoV-2 Spike Protein Enhances Carboxypeptidase Activity of Angiotensin-Converting Enzyme 2.

Mendiola-Salazar X, Munguia-Laguna M, Franco M, Cano-Martinez A, Santamaria Sosa J, Bautista-Perez R Int J Mol Sci. 2024; 25(11).

PMID: 38892464 PMC: 11172802. DOI: 10.3390/ijms25116276.


The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review.

Luo D, Bai M, Zhang W, Wang J Front Cardiovasc Med. 2024; 11:1409723.

PMID: 38863899 PMC: 11165996. DOI: 10.3389/fcvm.2024.1409723.


Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases?.

Avila-Martinez D, Mixtega-Ruiz W, Hurtado-Capetillo J, Lopez-Franco O, Flores-Munoz M Front Pharmacol. 2024; 15:1377113.

PMID: 38666016 PMC: 11044688. DOI: 10.3389/fphar.2024.1377113.


Role of the RAAS in mediating the pathophysiology of COVID-19.

Jasiczek J, Doroszko A, Trocha T, Trocha M Pharmacol Rep. 2024; 76(3):475-486.

PMID: 38652364 PMC: 11126499. DOI: 10.1007/s43440-024-00596-3.